Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Active oligopeptide GRGDS and application thereof in preparation of drug for preventing and treating ischemic cerebrovascular diseases

A cerebrovascular disease and ischemic technology, which is applied in the field of active short peptides, namely GRGDS, for the preparation of anti-ischemic cerebrovascular disease products, and achieves the effect of good application prospects.

Inactive Publication Date: 2020-12-29
上海萃微生物医药科技有限公司
View PDF0 Cites 1 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

[0007] The technical problem to be solved in this discovery is to disclose the new application of the active short peptide GRGDS, that is, the active short peptide has a new function of anti-ischemic cerebrovascular disease, and can be used to prepare anti-ischemic cerebrovascular disease products, Provide more effective products for the prevention, protection and treatment of ischemic cerebrovascular diseases

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Active oligopeptide GRGDS and application thereof in preparation of drug for preventing and treating ischemic cerebrovascular diseases
  • Active oligopeptide GRGDS and application thereof in preparation of drug for preventing and treating ischemic cerebrovascular diseases
  • Active oligopeptide GRGDS and application thereof in preparation of drug for preventing and treating ischemic cerebrovascular diseases

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0024] Embodiment 1: the preparation method of active short peptide GRGDS

[0025] Amino acid sequence: Gly-Arg-Gly-Asp-Ser (GRGDS)

[0026] The above polypeptide molecules were synthesized by China Peptide Biochemical Co., Ltd., with a purity of more than 98%.

Embodiment 2

[0027] Embodiment 2: GRGDS is used for the animal experiment of treating ischemic cerebrovascular disease

[0028] Rat ischemia-reperfusion model is a commonly used animal experimental model to verify that drugs can prevent and treat ischemic cerebrovascular disease (Xu Shuyun, Bian Rulian, Chen Xiu. Pharmacological Experimental Methodology (Third Edition). People's Medical Publishing House, 2002: 1061- 1062.), so it was used to verify the protective effect of the active short peptide GRGDS on experimental cerebral ischemia in rats.

[0029] 1. Animals

[0030] Healthy male SD rats, weighing 200-250 g, were reared in groups of 6 rats / cage, and divided into 10 groups in total. Purchased from Shanghai Slack Experimental Animal Co., Ltd., quality certificate number (animal certificate number: SCXK (Shanghai) 2007-0005). Raised in a clean animal room.

[0031] 2. Drugs

[0032] Group the experimental rats into groups:

[0033] Sham operation group: given the same amount of no...

Embodiment 3

[0046] Embodiment 3: GRGDS is used in the cell experiment of treating ischemic cerebrovascular disease

[0047] 1. Experimental method

[0048] Select PC12 cells (rat nerve cells) in good growth state and spread them in 96-well plates. After culturing in a constant temperature incubator at 37°C for 16 hours, the normal group continued normal culture with new high-sugar DMEM medium; the OGD group was replaced with sugar-free DMEM medium, and cultured in hypoxia for 6 hours; the GRGDS group was added with 0.01ug / mL GRDGS was cultured in sugar-free DMEM medium for 6 hours in hypoxia. After the end of hypoxia, operate according to the instructions in the apoptosis kit, and then use flow cytometry to detect the apoptosis of cells in each group.

[0049] All data are represented by ± s, and statistical analysis was performed using t test.

[0050] 2. Experimental results

[0051] see attached image 3 , the total apoptosis rate in the normal group was (2.26±0.61)%; the total cell...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention relates to the technical field of medicine, food, reagents and the like, in particular to application of oligopeptide GRGDS in preparation of a drug for preventing and treating ischemiccerebrovascular diseases. Pharmacological tests of a rat local cerebral ischemia model show that the oligopeptide can significantly reduce the cerebral infarction volume of a cerebral ischemia rat, significantly improve the nerve injury of the rat after ischemia and reduce the apoptosis of nerve cells. The oligopeptide has a strong brain protection effect, is easy to penetrate through a blood brain barrier due to small molecular weight, and has remarkable advantages. Therefore, the oligopeptide GRGDS has good application prospects in preparation of the drug for preventing and treating ischemiccerebrovascular diseases.

Description

technical field [0001] The present invention relates to the technical fields of medicine, food, reagents, etc., in particular to the new use of an active short peptide, and more specifically to the use of an active short peptide, namely GRGDS, for the preparation of anti-ischemic cerebrovascular disease products new uses. Background technique [0002] Ischemic cerebrovascular disease (ischemic stroke) is one of the diseases with the highest morbidity, mortality and disability rate in the world, which greatly threatens the health and quality of life of human beings, especially the elderly, and has become a global Huge burden on society's health resources. Clinically, the mortality and disability rate of ischemic stroke has taken the first place among neurological diseases. At present, there are few effective drugs used in the treatment of ischemic cerebrovascular disease at home and abroad. Therefore, it is of great significance to carry out in-depth research on drug preve...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(China)
IPC IPC(8): A61K38/08C07K7/06A61P9/10A23L33/18
CPCA61K38/08A23L33/18A61P9/10C07K7/06
Inventor 孙为婕
Owner 上海萃微生物医药科技有限公司
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com